Voyager Therapeutics (NASDAQ:VYGR) is scheduled to be announcing its earnings results after the market closes on Thursday, February 25th. Analysts expect the company to announce earnings of ($0.52) per share for the quarter. Parties that wish to listen to the company’s conference call can do so using this link.
NASDAQ:VYGR opened at $6.68 on Tuesday. Voyager Therapeutics has a 52 week low of $6.26 and a 52 week high of $14.62. The stock has a market capitalization of $250.27 million, a PE ratio of -4.07 and a beta of 1.80. The stock’s 50-day moving average price is $7.89 and its 200-day moving average price is $9.60.
A number of research analysts have weighed in on the stock. Cantor Fitzgerald lowered shares of Voyager Therapeutics from an “overweight” rating to a “neutral” rating and decreased their target price for the stock from $15.00 to $10.00 in a research note on Wednesday, December 23rd. Raymond James lowered shares of Voyager Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Wednesday, December 23rd. Wedbush downgraded shares of Voyager Therapeutics from an “outperform” rating to a “neutral” rating and dropped their target price for the company from $13.00 to $6.00 in a report on Wednesday, February 3rd. Oppenheimer downgraded shares of Voyager Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Wednesday, November 11th. Finally, Chardan Capital dropped their price target on shares of Voyager Therapeutics from $15.00 to $6.50 and set a “neutral” rating for the company in a research note on Wednesday, February 3rd. Nine investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $12.29.
About Voyager Therapeutics
Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease.
Recommended Story: Fiduciary
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.